Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Off Label Use of Dapsone in SARS-CoV-2 Hospitalized Patients
NCT04918914Phase 1Unknown
- Sponsor
- Hunt Regional Medical Center
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dapsone in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and hypoxia (2 arms), sponsored by Hunt Regional Medical Center. Primary endpoint: Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment at 1 year. Status: unknown.
02
Drugs
dapsone
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)hypoxia
Beyond the preview
Go deeper on NCT04918914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918914.